Zoetis Inc.
ZTS
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $31.8B
$75.81
▼ -0.63%
P/E
12.49
Mkt Cap
$31.8B
52-Wk Range
$71.00–$152.97
52-Week Range
$71.00 - $152.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 50.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Global market leadership
- Comprehensive product portfolio
- Strong research and development capabilities
- Extensive veterinary distribution network
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Growing global demand for protein
Value
Fairly valued vs Large Cap Pharma peers
Momentum
Stable
-3.8% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Solid
2.76% yield
Smart-money signal
Who's buying ZTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 6, 2026
Reported EPS of $1.87 vs $1.85 consensus (+1.1% surprise). Revenue of $2.5B vs $2.5B expected (-1.3%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.1%
Revenue trend · last 8Q
—
+5%
+1%
+4%
+1%
+3%
+2%
+0%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.4B
$2.3B
$2.2B
$2.5B
$2.4B
$2.4B
$2.3B
$2.5B
Margins · last 8Q
Gross
72.7%
Operating
38.0%
Profit
28.0%
Wall Street consensus
7 analysts · 43% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
43%
Hold
57%
Sell
0%
Median Price Target
$94.00
▲ +24.0% vs $75.81
Latest: TD Cowen · $94.00 · Aug 25, 2026
1 analyst covering
vs Industry
How ZTS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related